GSK Stock Recent News
GSK LATEST HEADLINES
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Although the three major U.S. stock indexes have rebounded from their 2022 bear market lows, bargains can still be found. A relatively small amount of money can go a long way when it's invested in top-tier businesses.
Artificial intelligence is being used by the world's top drugmakers to speed up innovation in areas of high unmet medical need. GSK and Eli Lilly are both pioneers in the use of AI for drug discovery and development.
GSK GSK shares surged 6% in London action as the U.K. pharmaceutical said it reached a settlement over its Zantac heartburn medication litigation with a plaintiff in California ahead of the trial slated to start July 24 in state court. Other companies impacted by Zantac litigation fears, Haleon HLN, +1.28% and Sanofi SAN, +0.91%, also advanced though not by as much.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either GSK (GSK) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?
With a new trading month already in full swing it is time, once again, to highlight some of my potential stock purchases. With the market still having a tough time in 2023 we see no shortages of stocks that are becoming fairly valued to undervalued and boasting higher yields. This month, I continue to look at some of the same names in months past.
Decades after the first attempt was made, an RSV vaccine has finally been approved by the FDA.
GSK PLC (LSE:GSK, NYSE:GSK)'s growth outlook is being overlooked and the worst-case scenario for Zantac continues to be reflected in the share price. That's the view of Shore Capital which reiterated a buy on the pharma giant with a 1,850p share price target.
A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.